FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)

View source ↗

Summary

The FDA has approved a supplemental application for PADCEV EJFV (enfortumab vedotin) from Seagen, marking regulatory action on a supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• PADCEV EJFV (enfortumab vedotin)

Snippet

SUPPL AP for PADCEV EJFV (ENFORTUMAB VEDOTIN)